Biotech Values

[oc631]

Our HCV thesis on pricing has been that AbbVie will list price at parity, and that initial discounting would be limited between two players.

This UBS analyst is both gullible and wrong; ABBV has no intention of parity pricing their combo with Sovaldi/LDV. How could they parity price when GILD has a 8-week option? GILD will price first and ABBV will dictate share by how aggressively they counter on list price. Both companies will discount yet this sets the stage on how the market will breakdown between these two players.

What this analyst is suggesting borders on price fixing and collusion.